Merck Predicts $70B Pipeline Opportunity, Bristol Myers’ Opdivo Hits $10B Sales
Merck forecasts over $70 billion in commercial opportunities by 2030s beyond Keytruda’s 2028 patent expiry, doubling prior peak consensus. Bristol Myers’ Opdivo sales reached $10.05 billion in 2025, up 8% year-over-year, reinforcing competition in the PD-1 therapy market.
1. Merck’s Post-Keytruda Growth Outlook
Merck projects more than $70 billion in non-risk-adjusted commercial opportunities from its current pipeline by the mid-2030s, more than twice the prior peak consensus for Keytruda. Management highlighted late-stage assets—Capvaxive ($759 million 2025 sales), Winrevair ($1.4 billion) and Welireg ($716 million)—alongside a tripled phase III pipeline since 2021 and recent M&A deals adding Ohtuvayre and MK-1406.
2. Intensified PD-1 Competition Landscape
Keytruda’s 2028 loss of exclusivity will open the PD-1 market to rivals, including Bristol Myers’ Opdivo, which generated $10.05 billion in 2025 sales (up 8% YoY). Other competitors include Roche’s Tecentriq ($3.56 billion, +3%) and AstraZeneca’s Imfinzi ($6.06 billion, +28%), underscoring a crowded immuno-oncology field.
3. Implications for Bristol Myers
Bristol Myers must leverage Opdivo’s momentum and accelerate next-generation immunotherapies to defend market share against Merck’s expanding arsenal. Continued diversification of the oncology pipeline and strategic partnerships will be critical to offset potential pricing pressure and volume challenges post-Keytruda LOE.